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Abstract
Background: The intensity and frequency of cough remain unclear in interstitial lung disease (ILD). The aim of this
study was to evaluate the intensity and frequency of cough in idiopathic interstitial pneumonias (IIPs), connective
tissue disease-associated interstitial lung disease (CTD-ILD), and chronic hypersensitivity pneumonia (CHP), and
examine their associations with clinical indices.
Methods: In this cross-sectional study, the intensity and frequency of cough were evaluated using a 100-mm visual
analogue scale. Scores on the Leicester Cough Questionnaire, chronic dyspnoea scale, and a frequency scale for
symptoms of gastro-oesophageal reflux disease (FSSG) were collected. The correlations of cough intensity and
frequency with potential predictor variables were tested using bivariate and multiple logistic regression analysis.
Results: The study included 70 patients with IIPs, 49 with CTD-ILD, and 10 with CHP. Patients with IIPs had the
most severe cough intensity among the three patient groups. In patients with IIPs, both the intensity and frequency
of cough were negatively associated with the diffusing capacity of the lung for carbon monoxide and positively
with the Composite Physiologic Index (CPI). In CTD-ILD, both the intensity and frequency of cough were correlated
with a higher FSSG score. In multivariate analysis of patients with ILD, IIPs and the FSSG score were independently
associated with both components of cough, and CPI tended to be independently associated with cough frequency.
Finally, we examined the features of the differences between cough intensity and frequency in all patients with ILD.
Patients in whom cough frequency was predominant had a greater impairment of health status relative to other
patients.
Conclusions: Cough intensity was greater in IIPs than in other ILDs. Different clinical indices were associated with
patient-reported cough intensity and frequency according to the subtype of ILD. Cough frequency was more
strongly associated with health status than was cough intensity. These findings suggest that medical staff could
manage patients with ILD by considering cough-related factors when assessing the intensity and frequency of
cough.
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Background
Nonproductive cough is a prominent symptom of inter-
stitial lung disease (ILD) [1], and it has been suggested
that cough associated with ILD should be assessed in
clinical trials [2]. The prevalence of cough has been re-
ported to be as high as 84% in patients with idiopathic
pulmonary fibrosis (IPF) [3], 73% in those with
scleroderma-related ILD [4], and 83% in those with
chronic hypersensitivity pneumonitis (CHP) [5]. Al-
though cough is an important defense mechanism that
serves to remove foreign material from the airways,
chronic cough is associated with the impairment of
health-related quality of life (HRQoL) [6, 7]. Several
studies in patients with ILD have shown associations of
objective measurements of cough frequency and subject-
ive visual analogue scale (VAS) cough scores with
HRQoL [5, 8].
In addition to the impairment of HRQoL, cough in pa-
tients with ILD may correlate with either disease pro-
gression or augment the activation of profibrotic
mechanisms [9, 10]. Ryerson et al. reported that cough
in patients with IPF was an independent predictor of dis-
ease progression and might predict time until death or
need for lung transplantation [3]. Moreover, Theodore
et al. and Tashkin et al. found that an increasing fre-
quency of cough in patients with scleroderma-related
ILD was correlated with the extent of fibrosis observed
on high-resolution computed tomography (HRCT) im-
ages [4, 11].
The Leicester Cough Questionnaire (LCQ) [8] and
cough frequency monitoring [12] are both used to assess
cough in patients with IPF, in particular its frequency.
However, Froese et al. confirmed that both the intensity
and frequency of mechanical stress-related breathing im-
pacted on the activation of key fibrogenic mediators,
particularly transforming growth factor beta-1, in rat fi-
brotic tissue [13]. This suggests that it is important to
evaluate cough intensity as well as its frequency in pa-
tients with ILD. However, there is a paucity of data fo-
cusing on these two components of cough separately in
patients with ILD, and their correlations with baseline
clinical indices representing disease severity.
The aims of this study were to evaluate both the inten-
sity and frequency of cough in patients with ILD, and to
examine their association with clinical indices that in-
clude disease severity data.
Methods
Study design and population
To minimise selection bias, consecutive new patients
with ILD, i.e., idiopathic interstitial pneumonias (IIPs),
connective tissue disease-associated interstitial lung dis-
ease (CTD-ILD), or CHP were invited to participate in
this cross-sectional study. The study was performed at
Kyoto University Hospital between August 2015 and
March 2018. IIPs were diagnosed as previously described
[14–16]. IPF was diagnosed by either surgical lung bi-
opsy or HRCT according to the guidelines [17]. CHP
was diagnosed in multidisciplinary team discussions ac-
cording to the established criteria [18]. Patients who had
had a respiratory tract infection in the preceding month,
those who had lung cancer, postnasal drip, rhinitis, ca-
tarrhal symptoms, or a history of adult asthma, and
those younger than 20 years of age were excluded.
Measurements
Data were obtained from patient-completed question-
naires and electronic patient records. The intensity and
frequency of cough were evaluated using a 100-mm VAS
(0, no cough; 100, unbearable), which is the most com-
monly used tool to subjectively assess cough severity
[19]. The VAS was used in the standardised manner rec-
ommended by the CHEST Expert Cough Panel in 2015
[20]. Patients were asked to place a vertical mark on the
scale reflecting the intensity of their cough, and another
vertical mark indicating the frequency of their cough. To
explore the features underlying any difference between
the VAS scores for cough intensity and cough frequency,
we stratified patients into three categories using the fol-
lowing formula: (cough intensity) − (cough frequency),
defining a cough frequency-dominant group, ≤ − 10mm;
an equal cough severity group, − 9 mm to 9mm; and a
cough intensity-dominant group, ≥10 mm. We assessed
cough-specific HRQoL using the Japanese version of the
LCQ [21]. The total score on the LCQ ranges from 3 to
21, with lower scores indicating greater impairment of
health status as a result of cough. The LCQ has been
previously shown to have appropriate feasibility and sen-
sitivity; thus, it can be considered an appropriate clinical
outcome tool for use in clinical trials that include pa-
tients with ILD [22]. Permission to use the LCQ was ob-
tained from the developer (Dr Surinder Birring) and
translators (Drs Akio Niimi and Haruhiko Ogawa). Dys-
pnoea was assessed using the Medical Research Council
(MRC) chronic dyspnoea scale. The symptoms of gastro-
oesophageal reflux disease (GORD) were assessed using
the frequency scale for symptoms of GORD (FSSG) de-
veloped by Kusano et al. [23], which has been previously
used in studies of cough [24, 25]. This questionnaire
consists of 12 questions; the total score on the FSSG
ranges from 0 to 48, with higher scores indicating more
severe symptoms of GORD. We simultaneously collected
data on the intensity and frequency of cough, LCQ,
MRC chronic dyspnea scale, and FSSG scores. Add-
itional data, including for age, sex, body mass index,
smoking history, anamnesis, medication, and pulmonary
function tests performed within 3 months of the assess-
ment of cough intensity and frequency, were obtained
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from the clinical records. The pulmonary function tests
were performed using the CHESTAC system (Chest M.I.
Inc., Tokyo, Japan), and the diffusing capacity of the
lung for carbon monoxide (DLco) was determined by the
single-breath technique. The Composite Physiologic
Index (CPI) was used to predict the extent of fibrosis on
HRCT. The formula used to calculate the CPI is as fol-
lows: CPI = 91.0 − (0.65 × percent predicted DLCO)
− (0.53 × percent predicted forced vital capacity [FVC]) +
(0.34 × percentage of predicted forced expiratory volume
in 1 s [FEV1]) [26].
Statistical analysis
The sample size was determined by the correlation be-
tween the severity of cough and %FVC in patients with
IPF based on previous data [3]. However, there were few
reports available on the correlation between severity of
cough and %FVC in patients with ILD until the present
study. Therefore, we hypothesised a mild effect size of
0.3 with an alpha level of 5% and a power of 90% and
calculated that a minimum sample size of 113 would be
required for this study.
The data were compared between the three groups
using either the chi-square test or Fisher’s exact test for
categorical variables, and either one-way analysis of vari-
ance or the Kruskal–Wallis test for continuous variables.
If the one-way analysis of variance or Kruskal–Wallis
test result was significant, the three groups were com-
pared using either Tukey’s test or a Bonferroni-
corrected significance level of 1.6%. The correlations of
cough intensity and frequency with potential predictor
variables were tested using either the Mann–Whitney U
test or Spearman’s rank correlation coefficient as appro-
priate. After the cough intensity and frequency data were
converted to a dichotomous variable using the median
value, multiple logistic regression analysis was performed
to identify independent variables predicting cough inten-
sity and frequency. Only one variable in a set of variables
with a correlation coefficient > 0.5 was used in the multi-
variate logistic regression analysis because of multicolli-
nearity. Potential predictive variables were age, sex,
pack-years of smoking, body mass index, FSSG, MRC
chronic dyspnoea scale and CPI scores, use of gluco-
corticoid medication, antifibrotic therapy and proton
pump inhibitors, and type of ILD. Variables were se-
lected using a forward selection method based on the
likelihood ratio test. The goodness of fit of the model
was assessed using the Hosmer–Lemeshow test. Missing
data were not included in the analyses. The data are
expressed as the number and percentage, mean and
standard deviation, or median with the interquartile
range. All statistical analyses were performed using SPSS
software (version 25; IBM Corp., Armonk, NY, USA). A
p-value < 0.05 for a two-tailed test was considered statis-
tically significant.
Results
Patient characteristics and intensity and frequency of
cough
Twenty-one of 150 patients examined for eligibility were
excluded (9 with a respiratory tract infection in the pre-
ceding month, 1 with lung cancer, 6 with rhinitis, 3 with
a history of adult asthma, 1 with an acute exacerbation
of IPF in the previous month, and 1 with pneumoconi-
osis). Seventy patients with IIPs, 49 with CTD-ILD, and
10 with CHP were included in the study. The 70 patients
with IIPs included 36 (51.4%) with IPF, 2 (2.9%) with
idiopathic nonspecific interstitial pneumonia, 2 (2.9%)
with respiratory bronchiolitis-associated ILD, 1 (1.4%)
with desquamative interstitial pneumonia, 2 (2.9%) with
cryptogenic organising pneumonia, 5 (7.1%) with idio-
pathic pleuroparenchymal fibroelastosis, and 22 (31.4%)
with unclassifiable idiopathic interstitial pneumonia. The
49 patients with CTD-ILD included 15 (30.6%) with sys-
temic sclerosis (SSc), 10 (20.4%) with polymyositis or
dermatomyositis, 8 (16.3%) with Sjögren’s syndrome, 11
(22.4%) with rheumatoid arthritis, 1 (2.0%) with systemic
lupus erythematosus, and 4 (8.2%) with microscopic po-
lyangiitis. None of the patients were using angiotensin-
converting enzyme inhibitors.
Table 1 shows the characteristics and intensity and
frequency of cough in patients with IIPs, CTD-ILD, and
CHP. Patients in the IIP group were more likely to be
male and using an antifibrotic agent, and less likely to be
using either glucocorticoid or proton pump inhibitor
therapy than those in the CTD-ILD and CHP groups.
The patients with CTD-ILD had a less extensive pack-
year smoking history, higher FSSG scores, and better
pulmonary function test results (i.e., FEV1, total lung
capacity, and DLco) than those with IIPs. The patients
with CTD-ILD also had a greater total lung capacity
than those with CHP. Among the three subtypes of ILD,
the patients with the IIPs had the greatest intensity of
cough but not frequency of cough. Patient age, current
smoking, body mass index, MRC chronic dyspnoea scale,
CPI, and LCQ scores were not affected by the subtype of
ILD.
Factors associated with cough intensity and frequency
The unadjusted factors associated with intensity and fre-
quency of cough in ILD are shown in Tables 2 and 3, re-
spectively. In patients with IIPs, both the intensity and
frequency of cough were negatively associated with the
DLco and positively with the CPI. For patients with
CTD-ILD, the DLco and CPI were associated with cough
frequency, and both the intensity and frequency of
cough were associated with FSSG and the MRC chronic
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dyspnoea scale score. However, the association between
cough frequency and either DLco or MRC chronic dys-
pnoea scale score was rather weak (Spearman rho = −
0.287 for DLco and rho = 0.291 for the MRC chronic dys-
pnoea scale score) in patients with CTD-ILD. Of note is
that the association of cough intensity and frequency
with CPI (Fig. 1) and FSSG score (Fig. 2) was numeric-
ally weaker and stronger, respectively, in patients with
CTD-ILD than in those with IIPs. There was no signifi-
cant association of either the intensity or frequency of
cough with any variable in patients with CHP.
Table 4 shows the results of the multiple logistic re-
gression analysis of factors associated with the intensity
and frequency of cough in all patients with ILD. IIPs and
the FSSG score were independently associated with both
the intensity and frequency of cough. Furthermore, CPI
tended to be independently associated only with the fre-
quency of cough (p = 0.052).
Features of the differences between cough intensity and
frequency
Finally, we examined the features of the differences be-
tween cough intensity and frequency in all patients with
ILD (n = 129). There was a positive correlation between
cough intensity and cough frequency (Spearman rho =
0.801, p < 0.001), but notably, the cough frequency-
dominant group had significantly lower total and subdo-
main LCQ scores than either the equal cough severity
group or cough intensity-dominant group (Table 5). The
Spearman’s correlation coefficients between total LCQ
scores and intensity and frequency of cough were −
0.675 and − 0.762, respectively (both p < 0.001).
Table 1 Patient characteristics and intensity and frequency of cough
Variable IIPs (n = 70) CTD-ILD (n = 49) CHP (n = 10) p-value
Age, years, mean ± SD 69.4 ± 8.9 66.5 ± 11.4 71.3 ± 7.5 0.185
Male sex, n (%) 56 (80)* 13 (27) 7 (70) < 0.001
Current smoker, n (%) 9 (13) 1 (2) 0 (0) 0.082
Pack-years of smoking, median (IQR) 40 (16–52) 0 (0–15)† 16 (4–35) < 0.001
Body mass indexa, mean ± SD 24.1 ± 3.3 23.1 ± 3.6 23.2 ± 2.0 0.279
FSSG score, median (IQR) 3 (1–7) 6 (2–12)† 4 (1–4) 0.010
MRC chronic dyspnoea scale, median (IQR)b 1 (1–2) 1 (1–2) 1 (1–3) 0.824
Pulmonary function tests, % predicted, median (IQR)c
FEV1 82.9 (74.3–94.4) 94.2 (85.6–107.8)
† 87.6 (78.8–90.1) 0.012
FVC 85.2 (74.2–97.3) 93.6 (80.2–106.1) 73.6 (68.8–93.3) 0.090
TLC 70.1 (64.3–85.8) 97.1 (79.8–104.1)†‡ 68.5 (54.4–72.1) < 0.001
DLCO 49.2 (38.8–58.9) 55.2 (48.1–66.6)
† 56.0 (37.2–62.9) 0.024
Composite Physiologic Index, median (IQR)c 43.2 (30.5–52.8) 34.8 (31.1–47.5) 43.5 (34.5–51.2) 0.157
Medication, n (%)
Glucocorticoid 9 (13)* 30 (61) 4 (40) < 0.001
Antifibrotic agent 21 (30)* 0 (0) 2 (20) < 0.001
Proton pump inhibitor 21 (30)* 26 (53) 4 (40) 0.040
VAS score for cough, mm, median (IQR)
Intensity 31 (17–55)§ 24 (8–46) 18 (6–20) 0.048
Frequency 24 (10–46) 13 (5–30) 10 (3–18) 0.060
Leicester Cough Questionnaire score, median (IQR)
Physical 6.1 (5.5–6.4) 6.0 (5.0–6.5) 6.3 (6.0–6.6) 0.311
Psychological 6.6 (5.9–7.0) 6.3 (5.3–7.0) 6.8 (6.1–7.0) 0.378
Social 6.8 (6.0–7.0) 6.5 (5.3–7.0) 6.9 (6.0–7.0) 0.539
Total 19.3 (17.5–20.4) 18.7 (15.4–20.5) 19.6 (18.3–20.6) 0.447
The p-values are shown for across-group comparisons using one-way analysis of variance, the Kruskal-Wallis test, the chi-square test, or Fisher’s exact test as
appropriate. Using a nominal 5% level of statistical significance, multiple comparisons were made using a Bonferroni-corrected significance level of 1.6% (p <
0.016). CHP, chronic hypersensitivity pneumonia; CTD-ILD, connective tissue disease-associated interstitial lung disease; DLco, diffusing capacity of the lung for
carbon monoxide; FEV1, forced expiratory volume in 1 s; FSSG, frequency scale for symptoms of gastro-oesophageal reflux disease; FVC, forced vital capacity; IIPs,
idiopathic interstitial pneumonias; IQR, interquartile range; MRC, Medical Research Council; SD, standard deviation; TLC, total lung capacity; VAS, visual analogue
scale. aIIPs (n = 70), CTD-ILD (n = 49), CHP (n = 9); bIIPs (n = 69), CTD-ILD (n = 49), CHP (n = 10); cIIPs (n = 66), CTD-ILD (n = 48), CHP (n = 9). *p < 0.05 vs CTD-ILD or
CHP; †p < 0.016 vs IIPs; ‡p < 0.016 vs CHP; §p = 0.067 vs CTD-ILD, p = 0.043 vs CHP
Sato et al. BMC Pulmonary Medicine          (2019) 19:247 Page 4 of 10
Table 2 Unadjusted analysis of factors associated with cough intensity in patients with interstitial lung disease
Variable IIPs (n = 70) CTD-ILD (n = 49) CHP (n = 10) Combined
ρ p-value ρ p-value ρ p-value ρ p-value
Age, years −0.065 0.595 0.063 0.669 0.339 0.337 −0.003 0.973
Male sex – 0.644 – 0.658 – 0.833 – 0.737
Current smoker – 0.598 – 0.490 – – – 0.156
Pack-years of smoking −0.128 0.293 −0.144 0.323 −0.174 0.630 −0.031 0.728
Body mass indexa −0.297 0.013 −0.133 0.362 −0.025 0.949 −0.166 0.061
FSSG score 0.146 0.229 0.342 0.016 0.366 0.298 0.207 0.019
MRC chronic dyspnoea scaleb 0.154 0.208 0.325 0.023 0.007 0.986 0.208 0.018
Pulmonary function tests, % predictedc
FEV1 −0.118 0.344 0.021 0.887 0.097 0.805 −0.091 0.316
FVC −0.206 0.097 −0.068 0.647 0.084 0.831 −0.123 0.175
TLC −0.212 0.088 −0.011 0.943 −0.109 0.781 −0.186 0.040
DLCO −0.316 0.010 −0.223 0.128 −0.310 0.417 −0.311 < 0.001
Composite Physiologic Indexc 0.370 0.002 0.209 0.154 0.142 0.715 0.295 0.001
Medication
Glucocorticoid – 0.986 – 0.681 – 0.114 – 0.168
Antifibrotic agent – 0.590 – – – 0.431 – 0.114
Proton pump inhibitor – 0.156 – 0.074 – 0.830 – 0.057
The Spearman rank correlation was used to assess correlations between the data. The p-values for binary variables were determined using the Mann-Whitney U
test. CHP, chronic hypersensitivity pneumonia; CTD-ILD, connective tissue disease-associated interstitial lung disease; DLco, diffusing capacity of the lung for carbon
monoxide; FEV1, forced expiratory volume in 1 s; FSSG, frequency scale for the symptoms of gastro-oesophageal reflux disease; FVC, forced vital capacity; IIPs,
idiopathic interstitial pneumonias; MRC, Medical Research Council; TLC, total lung capacity. aIIPs (n = 70), CTD-ILD (n = 49), CHP (n = 9); bIIPs (n = 69), CTD-ILD (n =
49), CHP (n = 10); cIIPs (n = 66), CTD-ILD (n = 48), CHP (n = 9)
Table 3 Unadjusted analysis of factors associated with cough frequency in patients with interstitial lung disease
Variable IIPs (n = 70) CTD-ILD (n = 49) CHP (n = 10) Combined
ρ p-value ρ p-value ρ p-value ρ p-value
Age, years 0.017 0.890 0.222 0.125 −0.031 0.933 0.100 0.260
Male sex – 0.174 – 0.441 – 0.667 – 0.415
Current smoker – 0.079 – 0.857 – – – 0.037
Pack-years of smoking −0.013 0.916 −0.192 0.186 −0.107 0.769 −0.011 0.898
Body mass indexa −0.251 0.036 −0.174 0.232 0.326 0.391 −0.166 0.061
FSSG score 0.019 0.878 0.350 0.014 0.342 0.334 0.174 0.049
MRC chronic dyspnoea scaleb 0.071 0.561 0.291 0.042 0.356 0.312 0.173 0.051
Pulmonary function tests, % predictedc
FEV1 −0.083 0.508 −0.040 0.786 0.038 0.923 −0.098 0.279
FVC −0.160 0.201 −0.114 0.439 0.017 0.966 −0.120 0.187
TLC −0.236 0.056 0.028 0.849 −0.126 0.748 −0.172 0.057
DLCO −0.307 0.012 −0.287 0.048 −0.510 0.160 −0.328 < 0.001
Composite Physiologic Indexc 0.334 0.006 0.322 0.026 0.259 0.500 0.319 < 0.001
Medication
Glucocorticoid – 0.642 – 0.096 – 0.257 – 0.012
Antifibrotic agent – 0.362 – – – 0.066 – 0.049
Proton pump inhibitor – 0.847 – 0.241 – 0.915 – 0.582
The Spearman rank correlation was used to assess correlations between the data. The p-values for binary variables were determined using the Mann-Whitney U
test. CHP, chronic hypersensitivity pneumonia; CTD-ILD, connective tissue disease-associated interstitial lung disease; DLco, diffusing capacity of the lung for carbon
monoxide; FEV1, forced expiratory volume in 1 s; FSSG, frequency scale for the symptoms of gastro-oesophageal reflux disease; FVC, forced vital capacity; IIPs,
idiopathic interstitial pneumonias; MRC, Medical Research Council; TLC, total lung capacity. aIIPs (n = 70), CTD-ILD (n = 49), CHP (n = 9); bIIPs (n = 69), CTD-ILD (n =
49), CHP (n = 10); cIIPs (n = 66), CTD-ILD (n = 48), CHP (n = 9)
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Discussion
To the best of our knowledge, this is the first study to
examine cough intensity and frequency separately in pa-
tients with IIPs, CTD-ILD, or CHP. Cough intensity was
greatest in the group containing patients with IIPs; both
the intensity and frequency of cough were negatively as-
sociated with the DLco and positively with the CPI in
these patients. In patients with CTD-ILD, both compo-
nents of cough correlated significantly with a higher
FSSG score. In all patients with ILD, multiple logistic re-
gression analysis revealed independent associations of
IIPs and the FSSG score with both the intensity and fre-
quency of cough, and a tendency for an independent as-
sociation of CPI with the frequency of cough.
Furthermore, although cough intensity and frequency
behaved similarly overall, the total and subdomain LCQ
scores were significantly poorer in the cough frequency-
dominant group than in the other two groups.
Fig. 1 Association of intensity and frequency of cough with CPI. A statistically significant association was observed between intensity and
frequency of cough and CPI in patients with idiopathic interstitial pneumonias. However, in connective tissue disease-associated interstitial lung
disease, only the frequency of cough correlated with CPI. CPI, Composite Physiologic Index; CTD-ILD, connective tissue disease-associated
interstitial lung disease; IIPs, idiopathic interstitial pneumonias; VAS, visual analogue scale
Fig. 2 Association of intensity and frequency of cough with the FSSG score. A statistically significant association was observed between cough
intensity and frequency and the FSSG score in patients with connective tissue disease-associated interstitial lung disease, but not in idiopathic
interstitial pneumonias. CTD-ILD, connective tissue disease-associated interstitial lung disease; FSSG, frequency scale for symptoms of gastro-
oesophageal reflux disease; IIPs, idiopathic interstitial pneumonias; VAS, visual analogue scale
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Cheng et al. recently reported that the VAS score for
cough severity was higher in patients with either IPF or
CHP than in those with CTD (SSc)-ILD [5]. In the
present study, we demonstrated that patients with IIPs
had more intense cough than those with either CTD-
ILD or CHP (Table 1), and that IIPs but not the CPI was
an independent risk factor for the intensity of cough
(Table 4). A VAS was the tool most frequently used in
other studies to assess cough severity in patients with
ILD [5] [8]. In those studies, severity was not usually de-
fined clearly, but was assumed to relate to both the fre-
quency and intensity of cough [19]. Although cough
severity is not equivalent to cough intensity, the median
score for cough intensity in the patients with IIPs in the
present study (31 mm) was comparable with that for
cough severity in patients with IPF reported on by
Cheng et al. (39 mm) [5] and Key et al. (32 mm) [8].
In this study, CPI tended to be independently associ-
ated with the frequency of cough in patients with ILD.
Specifically, in patients with IIPs, both the intensity and
frequency of cough were associated with the CPI and
DLco, but not with FVC. We believe that no significant
correlation was found between FVC and either the in-
tensity or frequency of cough because of the mainten-
ance of FVC in patients with ILD in this study. The CPI
has been reported to correlate more strongly than the
individual pulmonary function tests with the extent of
disease seen on computed tomography scans in patients
with IPF [26]. Therefore, it is possible that the severity
of cough may be associated with the extent of the paren-
chymal lesions in IIPs. When compared with patients
with CTD-ILD, there was also a numerically stronger as-
sociation of both the intensity and frequency of cough
with CPI in patients with IIPs (Fig. 1). Like our findings
in patients with IIPs, Cheng et al. reported a significant
correlation of cough severity with DLco in patients with
IPF [5]. Although our results do not indicate a causal re-
lationship between the intensity and frequency of cough
and CPI, Ryerson et al. showed that cough in patients
with IPF is an independent predictor of disease progres-
sion, which was defined as a 15% decline in DLco, a 10%
decline in FVC, or lung transplantation or death attrib-
utable to any cause [3]. Moreover, it has been suggested
that the fibroblastic foci that develop in IPF may result
from stretch injury at the epithelial-mesenchymal inter-
face [27]. It was also found that both the intensity and
frequency of mechanical stress-related breathing resulted
in activation of transforming growth factor beta-1 in rat
fibrotic tissue; when forces of 5–20 mN were applied to
fibrotic lung strips, active transforming growth factor
beta-1 increased significantly in response to the mechan-
ical stimulus [13]. Therefore, an increase in the intensity
and frequency of cough that causes mechanical stress
might contribute to disease progression, such as an in-
crease in CPI, in patients with IIPs.
Alternatively, cough in patients with IIPs might be a
consequence of architectural distortion of the fibrotic
lung. Traction bronchiectasis is caused by constriction
of the surrounding fibrotic alveolar tissue, and such
architectural distortion of the bronchial tree may be in-
volved in the activation of rapidly adapting receptors
[10, 28], resulting in an exaggerated coughing response,
i.e., an increase in either cough intensity or frequency.
Further studies are required to evaluate the correlation
between the extent of disease seen on HRCT and the in-
tensity and frequency of cough in patients with IIPs.
The FSSG score was another independent risk factor
for both the frequency and intensity of cough in patients
with ILD, particularly in patients with CTD-ILD. This
finding is consistent with that of Tashkin et al., suggest-
ing that the frequency of cough relates to the severity of
GORD at baseline and declines in parallel with an im-
provement in GORD by treatment for SSc-ILD [11].
Furthermore, a study in patients with SSc-ILD reported
a relationship between the degree of pulmonary fibrosis
assessed using a validated HRCT score and the number
of reflux episodes in the distal and proximal oesophagus
[29]. Hence, the well-known interaction between GORD
and cough [30] may be closely involved in the pathogen-
esis of CTD-ILD, particularly SSc-ILD. Meanwhile, FSSG
scores were lower in patients with IIPs than those in pa-
tients with CTD-ILD, and there was no significant
Table 4 Multivariable analysis of factors associated with cough intensity and frequency in interstitial lung disease
Variable Intensityc Frequencyc
AORa 95% CI p-
value
AORa 95% CI p-
valueLower Upper Lower Upper
Model (n = 122)a
IIPsb 3.727 1.689 8.223 0.001 3.166 1.422 7.050 0.005
FSSG score 1.083 1.013 1.157 0.020 1.086 1.014 1.162 0.018
Composite Physiologic Index – – – – 1.029 1.000 1.060 0.052
AOR, adjusted odds ratio; CI, confidence interval; FSSG, frequency scale for symptoms of gastro-oesophageal reflux disease; IIPs, idiopathic interstitial pneumonias.
aHosmer and Lemeshow test for cough intensity and frequency, p = 0.175 and p = 0.972, respectively. bConnective tissue disease-associated interstitial lung
disease or chronic hypersensitivity pneumonia as reference category. cThe data for intensity and frequency of cough were divided at the median to create
categorical variables
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correlation of either intensity or frequency of cough with
the FSSG score in patients with IIPs in the present
study. Another study found that only 25% of patients
with IPF and increased exposure to acid in the
oesophagus reported typical reflux symptoms [31]. A
further study found no association between GORD and
cough in patients with IPF [3]. Therefore, the impact
and association of GORD with cough may be weaker in
patients with IIPs than in those with CTD-ILD, even
though GORD is thought to be involved in the patho-
genesis of IIPs [32].
Patients with ILD and frequency-dominant cough had
a greater impairment of health status than those in the
other groups. Numerically, there was a stronger correl-
ation between cough frequency and total LCQ scores
than between cough intensity and total LCQ scores. Our
results concur with a report by Key et al. that demon-
strated a strong correlation between the objective cough
count and cough-related HRQoL in patients with IPF
[8]. Furthermore, given the tendency for an association
between frequency of cough and the CPI in patients with
ILD in the present study, it is reasonable to assess the
Table 5 Features of differences between cough intensity and frequency
Cough frequency-dominant group Equal cough severity group Cough intensity-dominant group p-
value
(n = 12) (n = 79) (n = 38)
Type of interstitial lung disease, n (%) 0.858
IIPs 7 (58) 41 (52) 22 (58)
CTD-ILD 5 (42) 30 (38) 14 (37)
CHP 0 8 (10) 2 (5)
Age, years, median (IQR) 73 (67–79) 70 (65–75) 65 (59–74) 0.048
Male sex, n (%) 7 (58) 47 (56) 22 (58) 0.986
Current smoker, n (%) 3 (25) 4 (5) 3 (8) 0.091
Pack-years of smoking, median (IQR) 13 (0–53) 22 (0–44) 20 (2–40) 0.925
Body mass indexa, mean ± SD 22.7 ± 3.8 24.1 ± 3.3 23.1 ± 3.2 0.162
FSSG score, median (IQR) 8 (0–10) 3 (1–6) 5 (2–12) 0.158
MRC chronic dyspnoea scale, median (IQR)a 2 (2–3) 1 (1–2) 1 (1–3) 0.036
Pulmonary function tests, % predicted, mean ± SDb
FEV1 87.2 ± 20.6 89.2 ± 19.1 87.7 ± 21.5 0.903
FVC 88.0 ± 24.3 89.8 ± 20.4 86.0 ± 20.4 0.664
TLC 85.0 ± 24.0 83.2 ± 21.8 78.1 ± 22.8 0.476
DLCO 50.9 ± 13.7 54.3 ± 15.5 50.7 ± 15.7 0.464
Composite Physiologic Index, mean ± SDb 40.9 ± 16.2 38.8 ± 13.6 42.3 ± 13.1 0.454
Medication, n (%)
Glucocorticoid 1 (8) 27 (34) 15 (40) 0.132
Antifibrotic agent 2 (17) 13 (17) 8 (21) 0.826
Proton pump inhibitor 4 (33) 28 (35) 19 (50) 0.288
VAS score for cough, mm, median (IQR)
Intensity 38 (26–45)* 15 (7–30) 54 (32–64)* < 0.001
Frequency 67 (64–82)*† 14 (5–30) 21 (10–32) < 0.001
Leicester Cough Questionnaire score, median (IQR)
Physical 4.8 (3.4–5.7)*† 6.3 (5.9–6.6) 5.9 (5.3–6.4)* < 0.001
Psychological 4.9 (3.9–6.4)* 6.7 (6.0–7.0) 6.3 (5.7–6.9) 0.002
Social 4.9 (3.9–6.1)*† 7.0 (6.0–7.0) 6.6 (5.5–7.0) 0.001
Total 13.9 (11.1–18.2)*† 19.6 (18.0–20.6) 18.7 (17.1–20.1) < 0.001
To explore the features associated with a differences between the VAS scores for cough intensity and cough frequency, we stratified patients into three categories
using the following formula: (cough intensity) − (cough frequency), defining a cough frequency-dominant group, ≤10 mm; an equal cough severity group, −9 mm
to 9mm; and a cough intensity-dominant group, ≥10 mm. p-values are shown for across-group comparisons using one-way analysis of variance, the Kruskal-Wallis
test, chi-square test, or Fisher’s exact test as appropriate. Using a nominal 5% level of statistical significance, multiple comparisons were made using a Bonferroni-
corrected significance level of 1.6% (p < 0.016). CHP, chronic hypersensitivity pneumonia; CTD-ILD, connective tissue disease-associated interstitial lung disease;
DLco, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FSSG, frequency scale for symptoms of gastro-oesophageal reflux
disease; FVC, forced vital capacity; IIPs, idiopathic interstitial pneumonias; IQR, interquartile range; MRC, Medical Research Council; SD, standard deviation; TLC,
total lung capacity; VAS, visual analogue scale. aCough frequency-dominant group (n = 12), equal cough severity group (n = 78), cough intensity-dominant group
(n = 38); bCough frequency-dominant group (n = 11), equal cough severity group (n = 77), cough intensity-dominant group (n = 35). *p < 0.016 vs equal cough
severity group; †p < 0.016 vs cough intensity-dominant group
Sato et al. BMC Pulmonary Medicine          (2019) 19:247 Page 8 of 10
frequency of cough in patients with ILD in a clinical set-
ting. However, we should not neglect cough intensity.
The physical domain scores of the LCQ were signifi-
cantly poorer in the cough intensity-dominant group
than in the group with equal cough severity (Table 5).
Furthermore, the intensity of cough also showed a sig-
nificant correlation with total LCQ scores in patients
with ILD. Finally, in patients with IIPs, cough intensity,
which was severest in the three subtypes of ILD, was as
significantly associated with DLco and CPI as cough fre-
quency. These findings highlight the need for the assess-
ment of both the intensity and frequency of cough in
patients with ILD, particularly for patients with IIPs.
The strengths of this study are that it addressed both
the intensity and frequency of cough in patients with
ILD and included an analysis of the subtypes of ILD (i.e.,
IIPs, CTD-ILD, and CHP). However, the study also has
several limitations. First, the small numbers of patients
with CHP may limit the generalisability of the results
obtained. Second, we did not investigate whether or not
patients had sputum present. Third, the study had a
cross-sectional design that precluded the identification
of either a temporal or causal relationship. Prospective
and longitudinal studies that include additional charac-
teristics of cough (e.g., production of sputum and dur-
ation) are needed. Fourth, the correlation coefficients in
the bivariate analysis were low. Therefore, the relation-
ship between cough intensity and frequency and clinical
indices identified in this study requires further investiga-
tion. Fifth, there was a risk of loss of statistical power
when continuous variables were dichotomised for multi-
variate analysis. However, dichotomisation was the best
way of performing a multivariate analysis to identify in-
dependent predictors of cough intensity and frequency
in this study because the raw data and log-transformed
data for these two variables were not normally distrib-
uted. Finally, we only used subjective tools to assess the
intensity and frequency of cough. Further research that
includes the use of both subjective and objective tools is
needed.
Conclusions
We found that the degrees of patient-reported cough inten-
sity and frequency and their associations with clinical indi-
ces representing disease severity were different for each
type of ILD. We also found independent associations of
IIPs and the FSSG score with both the intensity and fre-
quency of cough, and a tendency for an independent asso-
ciation of the CPI with the frequency of cough in patients
with ILD. Furthermore, impairment of cough-specific
HRQoL was noted in the cough frequency-dominant
group. These findings suggest that medical staff could man-
age patients with ILD by considering cough-related factors
when assessing the intensity and frequency of cough.
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